Key terms

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ABBV news

Today 6:20am ET AbbVie upgraded to Outperform from Market Perform at Leerink by TipRanks Today 6:11am ET AbbVie upgraded to Outperform from Market Perform at Leerink by TipRanks Nov 19 5:58am ET 3 Best Stocks to Buy Now, 11/19/2024, According to Top Analysts by TipRanks Nov 18 9:05am ET Wells Fargo Reaffirms Their Buy Rating on AbbVie (ABBV) by TipRanks Nov 18 5:30am ET AbbVie receives EC approval of Elahere by TipRanks Nov 14 6:55pm ET Wolfe starts AbbVie at Outperform, says valuation an attractive entry point by TipRanks Nov 14 4:11pm ET AbbVie initiated with an Outperform at Wolfe Research by TipRanks Nov 13 6:50am ET JPMorgan trims AbbVie target, removes from Analyst Focus List by TipRanks Nov 13 2:07am ET AbbVie Hold Rating Maintained Amid Emraclidine Trial Challenges and Competitive Pressure by TipRanks Nov 12 12:05pm ET Elliott confirms big Honeywell stake, Home Deport reports Q3 beat: Morning Buzz by TipRanks Nov 12 9:45am ET Bristol Myers price target raised to $61 from $57 at BMO Capital by TipRanks Nov 12 9:45am ET Nvidia initiated, Airbnb downgraded: Wall Street’s top analyst calls by TipRanks Nov 12 8:45am ET AbbVie price target lowered to $208 from $228 at BMO Capital by TipRanks Nov 12 7:31am ET Bristol Myers price target raised to $39 from $36 at Morgan Stanley by TipRanks Nov 12 7:31am ET AbbVie price target lowered to $224 from $231 at Morgan Stanley by TipRanks Nov 12 6:20am ET Leerink upgrades Bristol to Outperform after AbbVie schizophrenia failure by TipRanks Nov 12 6:08am ET AbbVie Buy Rating Affirmed Despite Emraclidine Setback, Driven by Skyrizi and Rinvoq Growth by TipRanks Nov 12 6:06am ET Positive Outlook on AbbVie: Geoff Meacham’s Buy Rating and Potential of Emraclidine Amid Schizophrenia Trial Challenges by TipRanks Nov 12 6:00am ET AbbVie price target lowered to $215 from $226 at Citi by TipRanks Nov 11 12:06pm ET Cigna drops pursuit of Humana: Morning Buzz by TipRanks Nov 11 11:35am ET Evercore says failure of emraclidine ‘may’ be ‘substantial’ Neurocrine positive by TipRanks Nov 11 11:10am ET AbbVie under pressure as schizophrenia drug fails two trials by TipRanks Nov 11 10:35am ET Leerink sees AbbVie’s trial results as ‘clear positive’ for Bristol Myers by TipRanks Nov 11 10:15am ET Barclays still likes AbbVie into 2025 despite schizophrenia failures by TipRanks Nov 11 10:15am ET Positive Long-Term Growth Outlook for AbbVie Despite Emraclidine Setback: Analyst Maintains Buy Rating by TipRanks Nov 11 10:15am ET JPMorgan sees AbbVie off about 10%, Bristol up 10%-15% on emraclidine news by TipRanks Nov 11 10:06am ET AbbVie falls -12.2% by TipRanks Nov 11 10:05am ET AbbVie ‘pain’ is Bristol Myers ‘gain’ after emraclidine fails, says Truist by TipRanks Nov 11 9:50am ET AbbVie falls -11.1% by TipRanks Nov 11 9:45am ET Bristol Myers rises, AbbVie sinks after schizophrenia trials miss targets by TipRanks Nov 11 8:35am ET AbbVie’s emraclidine did not meet endpoint in Phase 2 schizophrenia trials by TipRanks
Nov 20 9:00am ET Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? by Zacks Nov 19 10:00am ET ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap by Zacks Nov 18 10:17am ET AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe by Zacks Nov 15 3:00pm ET Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback by Zacks Nov 15 10:08am ET AbbVie Stock Falls 11% in a Month: Should You Buy the Dip? by Zacks Nov 15 6:20am ET Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar? by Zacks Nov 14 10:24am ET Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal by Zacks Nov 12 9:30am ET AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains by Zacks Nov 12 7:13am ET Company News for Nov 12, 2024 by Zacks Nov 08 11:03am ET Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down by Zacks Nov 08 9:40am ET Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? by Zacks Nov 08 9:30am ET Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy? by Zacks Nov 08 7:24am ET Zacks Investment Ideas feature highlights: AbbVie, Visa and Comfort Systems USA by Zacks Nov 07 4:47pm ET Dividend Watch: Three Companies Boosting Quarterly Payouts by Zacks Nov 07 11:40am ET RHHBY or ABBV: Which Is the Better Value Stock Right Now? by Zacks Nov 07 8:50am ET TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase by Zacks Nov 05 9:00am ET Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now? by Zacks Nov 04 3:00pm ET Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost? by Zacks Nov 01 3:00pm ET Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus by Zacks Nov 01 7:44am ET 5 Stocks That Recently Announced Dividend Hikes by Zacks Oct 31 6:20am ET Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now? by Zacks Oct 30 12:05pm ET AbbVie Trumps Q3 Earnings & Sales Estimates, Raises '24 EPS View by Zacks Oct 30 10:30am ET Compared to Estimates, AbbVie (ABBV) Q3 Earnings: A Look at Key Metrics by Zacks Oct 30 8:50am ET AbbVie (ABBV) Surpasses Q3 Earnings and Revenue Estimates by Zacks Oct 29 7:55am ET Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates by Zacks Oct 28 12:06pm ET Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts? by Zacks Oct 25 12:42pm ET Merck to Report Q3 Earnings: To Buy or Not to Buy MRK Stock? by Zacks Oct 25 9:16am ET Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings? by Zacks Oct 25 9:15am ET Curious about AbbVie (ABBV) Q3 Performance? Explore Wall Street Estimates for Key Metrics by Zacks Oct 24 5:45pm ET AbbVie (ABBV) Outperforms Broader Market: What You Need to Know by Zacks Oct 23 10:01am ET Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for by Zacks

ABBV Financials

1-year income & revenue

Key terms

ABBV Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ABBV Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Target expects a sluggish holiday season.
David Paul Morris/Bloomberg/Getty Images
Target sounds the alarm bell on holiday shopping
Investors piled into safe havens like gold and US debt as tensions rose in Europe. Gold prices jumped on Tuesday and US Treasury rates dipped.
Angela Weiss/AFP/Getty Images
Stocks shrug off concerns about heightened US-Russia tensions
A lone shopper places items in her cart in the frozen food aisle of a Walmart store Thursday, Nov. 14, 2024, in Englewood, Colo.
David Zalubowski/AP
As Americans bargain shop, six-figure earners flock to Walmart
NEW YORK, NEW YORK - JULY 07: Bikes with Grubhub bags sit on the street on July 07, 2023 in New York City. Grubhub, DoorDash and Uber Eats sued the City of New York on July 6th in order to block its new minimum pay rules for food delivery workers. (Photo by Leonardo Munoz/VIEWpress)
Leonardo Munoz/VIEWpress/Getty Images
Grubhub just sold for $650 million. Four years ago it was worth $7.3 billion